A West Virginia overview of physician-supervised GLP-1 treatment through Astra, including local access context and the cities we cover. Every statistic on this page links to its source.
West Virginia's adult obesity rate reached 41.4% in 2024, according to the CDC's Behavioral Risk Factor Surveillance System (n=5,473, 95% CI 39.8–43.0%) — up from 39.1% in 2020, 40.6% in 2021, 41.0% in 2022, and 41.2% in 2023 4. That five-year climb puts West Virginia among the states with the highest recorded obesity prevalence in the country.
The state's population has moved in the opposite direction: 1,769,979 residents as of July 1, 2024, down from 1,793,736 in April 2020 — a loss of roughly 23,700 people (-1.3%) even as the U.S. as a whole grew 56. A shrinking, aging population carrying a rising obesity burden is the specific shape of West Virginia's problem.
Not for weight loss as a standalone indication. Both of the state's Bureau for Medical Services prior-authorization documents say so in nearly identical language: "Agents used for the purpose of weight loss are typically a benefit exclusion" 12. Coverage exists only through two narrow carve-outs tied to specific diagnoses, not to obesity itself.
Wegovy (semaglutide), effective 1/01/2026, is payable only for secondary prevention of a major cardiovascular event — established cardiovascular disease, BMI ≥27, a documented prior heart attack, stroke, or symptomatic peripheral artery disease, and prescribing by or with a cardiology, vascular surgery, or neurology specialist — or for biopsy- or elastography-confirmed MASH (moderate-to-advanced F2-F3 liver fibrosis) prescribed by or with GI or hepatology. Patients with diabetes are excluded from the cardiovascular pathway 13.
Zepbound (tirzepatide), effective 7/01/2025, is payable only for moderate-to-severe obstructive sleep apnea — an AHI of 15 or higher on a sleep study within the past 12 months, BMI ≥30, prior CPAP counseling, chronic weight-management counseling, and, for diabetics, documented three-month treatment failure on a preferred diabetes GLP-1 23. Plain diet-and-exercise obesity treatment, with no qualifying cardiovascular, liver, or sleep-apnea diagnosis, is excluded under both drugs' criteria as written. For most West Virginians seeking weight loss alone, Medicaid is not a coverage path.
Because Medicaid coverage is this narrow, most West Virginians pursuing GLP-1 treatment for weight loss are paying out of pocket, either through a local clinic or a telehealth provider. Astra's price in West Virginia is the price everywhere else we operate: $68 a month for compounded semaglutide and $118 a month for compounded tirzepatide, both on 12-month plans billed annually at $816 and $1,416, the same at every dose. There is no West Virginia price list, no regional surcharge, and no local discount.
With West Virginia's median household income at $60,798, ±$1,120 margin of error on ACS 2024 1-year estimates 7 — among the lower figures of any state — the gap between Medicaid's narrow coverage and a full-price prescription is a real affordability question for many households here, not an abstract one. The state's uninsured rate is about 5.8% 8, computed by summing the 18 age/sex "no health insurance coverage" cells in ACS 2024 1-year Table B27001 — a derived estimate, not a single published headline statistic.
West Virginia's own Medicaid criteria point to the access problem indirectly: qualifying for either GLP-1 carve-out requires sign-off from a cardiology, vascular surgery, neurology, GI, hepatology, or sleep-medicine specialist — exactly the subspecialty care hardest to reach in a state that has lost population every year this decade and remains predominantly rural 125.
Data gap, stated plainly: HRSA state-level Health Professional Shortage Area figures for West Virginia were not verified for this page. The data.hrsa.gov shortage-area API endpoints returned 404 and the shortage-area finder requires interactive filtering rather than a direct query URL. That's a gap pending a follow-up pull, not a number we're going to estimate.
The rules a telehealth prescriber must follow here are set by the West Virginia Board of Medicine and the West Virginia Board of Osteopathic Medicine. TODO before publish: confirm the current telehealth-prescribing requirements — initial-visit modality, follow-up cadence — that apply to GLP-1 prescribing. We have not independently verified the current text of those rules for this page, so check the boards directly for specifics rather than reading a rule summary here.
What is confirmed: Astra is licensed to treat patients in West Virginia, along with all 50 states — statewide, not just Charleston, and with no in-person visit required.
Astra treats patients in West Virginia through state-licensed physicians.
Charleston, the state capital and second-most-populous city, is the first West Virginia city hub we've built: local GLP-1 pricing we've verified, with sources and the dates we checked them.
Not for weight loss alone. West Virginia's Bureau for Medical Services explicitly excludes GLP-1/GIP drugs used "for the purpose of weight loss." Wegovy is payable only for secondary cardiovascular-event prevention or confirmed MASH liver disease; Zepbound only for moderate-to-severe obstructive sleep apnea. Most people seeking treatment for obesity alone will not qualify under either pathway.
No — and we won't pretend otherwise. Astra charges the same $68/month for semaglutide and $118/month for tirzepatide (12-month plans, billed annually at $816/$1,416) in every state and city we serve, including West Virginia. There's no West Virginia discount and no West Virginia markup.
Yes. Astra is licensed to serve patients in all 50 states, including West Virginia statewide — not just Charleston.
It depends on where you go. See our Charleston, WV page for the local clinic prices we've verified there, with sources and the date we checked them. Astra's own price is the same nationally: $68/month for semaglutide, $118/month for tirzepatide, both on 12-month plans.
The West Virginia Board of Medicine (wvbom.wv.gov) and the West Virginia Board of Osteopathic Medicine set prescribing requirements for telehealth providers in the state. We're still confirming the specific rules that apply to GLP-1 prescribing, so check their sites directly for the current text.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.